Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
This is a short extract from a report by MarketWatch. The full text stays with the publisher — follow the link to read it there.
Read at source